The genetic characterization of ccRCC tumors supported the development of an array of targeted therapies inhibiting the AKT-mTOR pathway12 or HIF target genes (particularly VEGF)13. The gene discussed is MTOR; the disease is nonpapillary renal cell carcinoma.